CURE and BioHaven Present Achillion: Transforming Innovation into Novel Therapies to Address Patient Needs

Presenting: Dr. Milind Deshpande Based in New Haven, Connecticut since 2001, Achillion Pharmaceuticals devotes their efforts to small molecule therapies. On behalf of the company, President and CEO Dr. Milind Deshpande discussed the recent particle development victories. Tracing back his journey as a scientist in the pharmaceutical industry, a good 20 years ago, he mentioned that the only thing known about the complement immune system was that “it existed”. Today, with the advancement in knowledge and science in general, we know about the many pathways involved in this system and the numerous proteins associated with it. Achillion’s remedies largely target [...]

By |July 8th, 2015|BioHaven, Blog|0 Comments

Transforming Pharmaceutical Development, Manufacturing and Distribution Through Low Cost Portable, Continuous, Miniature & Modular (PCM&M) Manufacturing Facilities

The CURE BioHaven meeting on 12th May gave voice to an innovative on-site manufacturing method that is designed for multiple products, rapid changeovers and flexible, batch-sized production-on-demand technology. The idea of manufacturing in pods promises to transform pharmaceutical development, manufacturing and distribution in general. It also anticipates overcoming the challenges currently faced by a processing based industry and speaks to the globalization of the pharmaceutical market. PCM&M, the simplified way of saying “Portable, Continuous, Miniature and Modular Manufacturing” seeks to maintain a balance between speed, cost and quality of the manufacturing process. The portable and modular aspects in design and [...]

By |May 15th, 2015|BioHaven, Event Highlights|0 Comments

Venture Capital Investing in the Life Sciences

CURE and Yale’s final BioHaven entrepreneurship lecture of the year drew out a large crowd of 150+ attendees and focused on venture capital (VC) investing in healthcare and life sciences. This BioHaven panel was convened to shed light on funding opportunities and investment strategies at different firms, from corporate VC to more traditional groups. Amogh Sivarapatna, a Yale PhD student in biomedical engineering and an Advanced Graduate Leadership Fellow in SOM, opened the event by discussing the challenges of creating and funding startups in healthcare and life sciences.  He commented on how some entrepreneurs are uncertain about starting companies in [...]

By |December 22nd, 2014|BioHaven, Event Highlights|0 Comments

Patients and Big Data in Healthcare: Deriving Value and Accelerating Innovation.

In November, CURE and Yale, in collaboration with Boehringer Ingelheim, presented “Patients and Big Data in Healthcare: Deriving Value and Accelerating Innovation.” This panel discussion, moderated by Richard Foster, PhD, Emeritus Director at McKinsey and Co and Lecturer at the Yale School of Management, brought together forward thinking minds from across healthcare industry and academia for a discussion on the challenges, successes, and potential that big data in medicine has to transform the way healthcare is delivered, and financed. “Big data” represents data that exceeds the conventional computing capacity of traditional database systems as a result of volume, velocity, or [...]

By |November 20th, 2014|BioHaven, Event Highlights|0 Comments

Translating medical technologies from the lab to the clinic: challenges and opportunities

This special October BioHaven brought together thought leaders from both academia and industry to focus on building high quality, scalable businesses in regenerative medicine. Regenerative medicine is not a new field, but rather a broad, interdisciplinary, translational branch of medicine and tissue engineering that focuses on replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. Whereas significant progress has been made over the past few decades, the commercial success of the field has been hampered due to complex nature of the products, the significant amount of capital needed and regulatory hurdles. The panelists for [...]

By |October 28th, 2014|BioHaven, Event Highlights|0 Comments

Challenges Facing Pharmaceutical R&D

At the first BioHaven of the season, CURE and Yale welcomed Dr. John LaMattina, former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. Dr. LaMattina spoke about how the major headwinds facing big pharma now, including lost revenues and decreased R&D productivity, ultimately affect all of us as patients. A [...]

By |September 15th, 2014|BioHaven, Event Highlights|0 Comments

BioHaven Entrepreneur Series Featured Melinta Therapeutics

On April 29th at the Yale School of Medicine’s Anlyan Center, CURE BioHaven Entrepreneur Series presented “Melinta Therapeutics: The Road from the Lab to New Medicines”. As one of the co-founding scientists, Dr. Thomas Steitz spoke about the scientific side of Melinta (formerly known as Rib-X Pharmaceuticals). Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. He was awarded the Nobel Prize in Chemistry in 2009 for studies of the structure and function of the ribosome, a molecular machine that translates genetic information encoded in DNA into proteins [...]

By |May 20th, 2014|BioHaven|0 Comments